168 related articles for article (PubMed ID: 38358742)
1. Primary Treatment Modification and Treatment Tolerability Among Older Chemotherapy Recipients With Advanced Cancer.
Mohamed MR; Rich DQ; Seplaki C; Lund JL; Flannery M; Culakova E; Magnuson A; Wells M; Tylock R; Mohile SG
JAMA Netw Open; 2024 Feb; 7(2):e2356106. PubMed ID: 38358742
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study.
Mohile SG; Mohamed MR; Xu H; Culakova E; Loh KP; Magnuson A; Flannery MA; Obrecht S; Gilmore N; Ramsdale E; Dunne RF; Wildes T; Plumb S; Patil A; Wells M; Lowenstein L; Janelsins M; Mustian K; Hopkins JO; Berenberg J; Anthony N; Dale W
Lancet; 2021 Nov; 398(10314):1894-1904. PubMed ID: 34741815
[TBL] [Abstract][Full Text] [Related]
4. An Unsupervised Machine Learning Approach to Evaluating the Association of Symptom Clusters With Adverse Outcomes Among Older Adults With Advanced Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Xu H; Mohamed M; Flannery M; Peppone L; Ramsdale E; Loh KP; Wells M; Jamieson L; Vogel VG; Hall BA; Mustian K; Mohile S; Culakova E
JAMA Netw Open; 2023 Mar; 6(3):e234198. PubMed ID: 36947036
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of and factors associated with treatment modification at first cycle in older adults with advanced cancer receiving palliative treatment.
Mohamed MR; Kyi K; Mohile SG; Xu H; Culakova E; Loh KP; Flannery M; Obrecht S; Ramsdale E; Patil A; Dunne RF; DiGiovanni G; Hezel A; Burnette B; Desai N; Giguere J; Magnuson A
J Geriatr Oncol; 2021 Nov; 12(8):1208-1213. PubMed ID: 34272204
[TBL] [Abstract][Full Text] [Related]
6. Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial.
Li D; Sun CL; Kim H; Soto-Perez-de-Celis E; Chung V; Koczywas M; Fakih M; Chao J; Cabrera Chien L; Charles K; Hughes SFDS; Katheria V; Trent M; Roberts E; Jayani R; Moreno J; Kelly C; Sedrak MS; Dale W
JAMA Oncol; 2021 Nov; 7(11):e214158. PubMed ID: 34591080
[TBL] [Abstract][Full Text] [Related]
7. Communication With Older Patients With Cancer Using Geriatric Assessment: A Cluster-Randomized Clinical Trial From the National Cancer Institute Community Oncology Research Program.
Mohile SG; Epstein RM; Hurria A; Heckler CE; Canin B; Culakova E; Duberstein P; Gilmore N; Xu H; Plumb S; Wells M; Lowenstein LM; Flannery MA; Janelsins M; Magnuson A; Loh KP; Kleckner AS; Mustian KM; Hopkins JO; Liu JJ; Geer J; Gorawara-Bhat R; Morrow GR; Dale W
JAMA Oncol; 2020 Feb; 6(2):196-204. PubMed ID: 31697365
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-Related Toxic Effects and Quality of Life and Physical Functioning in Older Patients.
Baltussen JC; de Glas NA; van Holstein Y; van der Elst M; Trompet S; Uit den Boogaard A; van der Plas-Krijgsman W; Labots G; Holterhues C; van der Bol JM; Mammatas LH; Liefers GJ; Slingerland M; van den Bos F; Mooijaart SP; Portielje JEA
JAMA Netw Open; 2023 Oct; 6(10):e2339116. PubMed ID: 37870832
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Association of Oncologist-Patient Communication With Functional Status and Physical Performance in Older Adults: A Secondary Analysis of a Cluster Randomized Clinical Trial.
Jensen-Battaglia M; Lei L; Xu H; Kehoe L; Patil A; Loh KP; Ramsdale E; Magnuson A; Kleckner AS; Wildes TM; Lin PJ; Mustian KM; Giri G; Whitehead M; Bearden J; Burnette BL; Geer J; Mohile SG; Dunne RF
JAMA Netw Open; 2022 Mar; 5(3):e223039. PubMed ID: 35302628
[TBL] [Abstract][Full Text] [Related]
11. A Geriatric Assessment Intervention to Reduce Treatment Toxicity Among Older Adults With Advanced Lung Cancer: A Subgroup Analysis From a Cluster Randomized Controlled Trial.
Presley CJ; Mohamed MR; Culakova E; Flannery M; Vibhakar PH; Hoyd R; Amini A; VanderWalde N; Wong ML; Tsubata Y; Spakowicz DJ; Mohile SG
Front Oncol; 2022; 12():835582. PubMed ID: 35433441
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
13. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
[TBL] [Abstract][Full Text] [Related]
15. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
[TBL] [Abstract][Full Text] [Related]
17. External Validation of Risk Factors for Unplanned Hospitalization in Older Adults With Advanced Cancer Receiving Chemotherapy.
Mohamed MR; Loh KP; Mohile SG; Sohn M; Webb T; Wells M; Yilmaz S; Tylock R; Culakova E; Magnuson A; Sun CL; Bearden J; Hopkins JO; Faller BA; Klepin HD
J Natl Compr Canc Netw; 2023 Mar; 21(3):273-280.e3. PubMed ID: 36898361
[TBL] [Abstract][Full Text] [Related]
18. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
19. Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma.
Rodday AM; Hahn T; Kumar AJ; Lindenauer PK; Friedberg JW; Evens AM; Parsons SK
JAMA Netw Open; 2021 Oct; 4(10):e2128373. PubMed ID: 34673965
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
